Montefiore Medical Center Bronx, New York, United States
Background/Case Studies: Evans syndrome is a rare autoimmune disorder marked by the coexistence of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), occasionally with immune neutropenia. It is diagnosed in fewer than 5% of patients initially presenting with either ITP or AIHA and presents significant diagnostic and therapeutic challenges. We report a complex case that underscores the importance of comprehensive evaluation and a high index of suspicion when approaching unexplained cytopenias.
Study
Design/Methods: A 32-year-old male with a history of childhood ITP, status post splenectomy in 2007, presented with fatigue, shortness of breath, and melena. Diagnosed with ITP at age 11, he had relapsed multiple times despite splenectomy and intermittent use of Eltrombopag and Vincristine. On admission, labs showed anemia with a positive Direct Coombs test (IgG+, C3-), warm autoantibody, panagglutinin, and thrombocytopenia. Other hemolytic indicators included low haptoglobin and mildly elevated LDH and bilirubin. The peripheral smear lacked spherocytes, which, along with the prior splenectomy, complicated the identification of a hemolytic process.
Blood transfusion was challenging due to the presence of panagglutinin and rare antigen phenotype (c-, E-, Fya-, Jkb-, K-). Extensive workup, including autoimmune panels, infectious screens, bone marrow biopsy, flow cytometry, and cytogenetics, was unremarkable. However, next-generation sequencing revealed a DNMT3A E774K mutation at 11.1% allele frequency.
The clinical picture supported a diagnosis of Evans syndrome (warm AIHA with IgG+, C3- and ITP). Treatment included IVIG, high-dose corticosteroids, erythropoietin, IV iron, platelet and antigen-matched RBC transfusions, and Rituximab, leading to clinical improvement and discharge.
Results/Findings: This case highlights the diagnostic complexity in patients with prior splenectomy, which can obscure typical hemolysis findings. While the presence of a DNMT3A mutation added another layer of complexity, no direct causal relationship between DNMT3A mutations and Evans syndrome is currently established. DNMT3A is most commonly associated with hematologic malignancies, and its presence may represent clonal hematopoiesis rather than a pathogenic mechanism for Evans syndrome. Some studies have noted DNMT3A mutations in isolated cases of Evans syndrome, but further investigation is needed to clarify any meaningful association. Conclusions: In conclusion, Evans syndrome requires a thorough diagnostic approach, particularly when typical hemolytic signs are masked, as in post-splenectomy cases. Though the significance of concurrent DNMT3A mutations remains unclear, their detection may offer insights into disease evolution and immune dysregulation. Continued research into the genomic underpinnings of Evans syndrome could enhance our understanding and guide more personalized therapeutic strategies.
